Pages that link to "Item:Q70261"
From MaRDI portal
The following pages link to Dose-Finding Based on Efficacy-Toxicity Trade-Offs (Q70261):
Displaying 20 items.
- DROID: dose-ranging approach to optimizing dose in oncology drug development (Q6589229) (← links)
- A seamless phase II/III design with dose optimization for oncology drug development (Q6618336) (← links)
- REDOMA: Bayesian random-effects dose-optimization meta-analysis using spike-and-slab priors (Q6618357) (← links)
- A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications (Q6622241) (← links)
- Combined criteria for dose optimisation in early phase clinical trials (Q6625215) (← links)
- Comparative review of novel model-assisted designs for phase I/II clinical trials (Q6625482) (← links)
- A Bayesian design for phase I cancer therapeutic vaccine trials (Q6625928) (← links)
- BIPSE: a biomarker-based phase I/II design for immunotherapy trials with progression-free survival endpoint (Q6626777) (← links)
- A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies (Q6627253) (← links)
- A phase I--II design based on periodic and continuous monitoring of disease status and the times to toxicity and death (Q6627403) (← links)
- Hybrid design evaluating new biomarkers when there is an existing screening test (Q6627744) (← links)
- Change-point joint model for identification of plateau of activity in early phase trials (Q6627755) (← links)
- uTPI: a utility-based toxicity probability interval design for phase I/II dose-finding trials (Q6627822) (← links)
- A Bayesian adaptive phase i/II platform trial design for pediatric immunotherapy trials (Q6627894) (← links)
- Seamless phase I/II design for novel anticancer agents with competing disease progression (Q6627954) (← links)
- Bayesian modeling of a bivariate toxicity outcome for early phase oncology trials evaluating dose regimens (Q6628011) (← links)
- TITE-BOIN12: a Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy (Q6628336) (← links)
- Utility based approach in individualized optimal dose selection using machine learning methods (Q6628609) (← links)
- Subgroup-specific dose finding for phase I-II trials using Bayesian clustering (Q6628623) (← links)
- Group sequential designs for clinical trials with bivariate endpoints (Q6629838) (← links)
